Patents Assigned to Oslo Universitetssykehus HF
-
Patent number: 11926614Abstract: The present invention relates to compounds of formula (I), tautomers, stereoisomers, pharmaceutically acceptable salts and pro-drugs thereof, to processes for their preparation, to pharmaceutical compositions containing such compounds and to their use in therapy wherein a dashed line indicates an optional bond; X represents: a 5- or 6-membered, unsaturated heterocyclic group optionally substituted by one or more (e.g. 1, 2 or 3) substituents independently selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (e.g. C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), C1-6 alkoxy (e.g. C1-3 alkoxy), —CN, —NO2, —N(R)2, and —SO2R (where each R is independently H or C1-6 alkyl, e.g. H or C1-3 alkyl); a C3-5 cycloalkyl group optionally substituted by one or more (e.g. 1 or 2) substituents independently selected from C1-6 alkyl (preferably C1-3 alkyl), C1-6 haloalkyl (e.g. C1-3 haloalkyl), and C1-6 alkoxy (e.g. C1-3 alkoxy); or an aryl group optionally substituted by one or more (e.g.Type: GrantFiled: June 19, 2019Date of Patent: March 12, 2024Assignees: OSLO UNIVERSITETSSYKEHUS HF, FORSCHUNGSVERBUND BERLIN E.V., UNIVERSITY OF OULUInventors: Stefan Krauss, Marc Nazare, Lari Lehtio, Jo Waaler, Anita Wegert, Ruben Gerardus George Leenders
-
Publication number: 20240009213Abstract: Provided herein is a leukocyte tyrosine kinase (LTK) inhibitor for use in the treatment of a viral infection in a subject, wherein the viral infection is caused by an RNA virus. Also provided are methods of treating a viral infection in a subject, wherein the viral infection is caused by an RNA virus, the method comprising administering to the subject an LTK inhibitor, and the use of an LTK inhibitor in the manufacture of a medicament for the treatment of a viral infection, wherein the viral infection is caused by an RNA virus. In particular, the infection may be an influenza or coronavirus infection in a human subject.Type: ApplicationFiled: September 30, 2021Publication date: January 11, 2024Applicants: OSLO UNIVERSITETSSYKEHUS HF, UNIVERSITETET I OSLOInventors: Hesso FARHAN, Ludvig MUNTHE, Gunnveig GRØDELAND, Ken ROSENDAL
-
Patent number: 11806330Abstract: Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.Type: GrantFiled: March 27, 2019Date of Patent: November 7, 2023Assignees: SINTEF TTO AS, OSLO UNIVERSITETSSYKEHUS HFInventors: Yrr Morch, Einar Sulheim, Kjersti Flatmark, Karianne Giller Fleten, Per Stenstad, Heidi Johnsen, Ruth Schmid
-
Publication number: 20230173029Abstract: The present invention provides a polypeptidic compound for use in prevention or treatment of cardiac remodeling in a subject, the polypeptidic compound comprising the amino acid sequence of proANP31-67, or an amino acid sequence having at least 80% sequence identity thereto.Type: ApplicationFiled: April 2, 2020Publication date: June 8, 2023Applicants: UNIVERSITETET I OSLO, OSLO UNIVERSITETSSYKEHUS HFInventors: Lawrence MAHAN, Alessandro CATALIOTTI, Raffaele ALTARA
-
Patent number: 11555222Abstract: The present invention provides a method of quantification of a target nucleic acid, using at least any two of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4 as control genes. In particular, the combination of the genes SYT10, EPHA3, PLEKHF1 and KBTBD4, known as the 4Plex, is provided as a control for nucleic acid quantification. The 4Plex has particular utility as a control for nucleic acid quantification by methylation-specific droplet digital PCR.Type: GrantFiled: November 30, 2018Date of Patent: January 17, 2023Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Guro E. Lind, Marine Jeanmougin, Heidi D. Pharo, Kim Andresen, Ragnhild Lothe
-
Patent number: 11543417Abstract: In some embodiments, the present invention provides chromatin immunoprecipitation (ChIP) methods. In particular, the present invention provides methods and compositions for performing ChIP (e.g., ChlP-seq) assays on small numbers or cells.Type: GrantFiled: August 29, 2017Date of Patent: January 3, 2023Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: John Arne Dahl, Arne Klungland
-
Patent number: 11452767Abstract: The present invention relates to CTL peptide epitopes, high-throughput methods for their identification, and their uses. In particular, the present invention relates to peptide epitopes for cancer immunotherapy and Hepatitis C Virus vaccines. The present invention also relates to methods and systems for identifying antigen-specific CTLs.Type: GrantFiled: November 14, 2014Date of Patent: September 27, 2022Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Johanna Olweus, Shraddha Kumari
-
Patent number: 11186641Abstract: The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.Type: GrantFiled: March 16, 2017Date of Patent: November 30, 2021Assignee: OSLO UNIVERSITETSSYKEHUS HFInventor: Anders Tveita
-
Patent number: 11155786Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.Type: GrantFiled: January 22, 2016Date of Patent: October 26, 2021Assignee: Oslo Universitetssykehus HFInventors: Sébastien Wälchli, Else Marit Inderberg Suso, Gustav Gaudernack, Gunnar Kvalheim
-
Patent number: 11138729Abstract: Dynamic contrast enhanced MRI data and dynamic susceptibility contrast MRI data for a volume of the patient's body including a tumor are used in order to identify the risk of lymph node metastasis. A volume of interest enclosing the tumor is identified and the MRI data for the volume of interest is processed in order to identify one or more parameters relating to the transverse relaxation rate and/or to dynamic changes in the transverse relaxation rate. A comparison is made to previously obtained similar parameters for other patients having similar tumors that are either known to exhibit lymph node metastasis or are known not to exhibit lymph node metastasis in order to determine if the MRI data indicates that the patient has a tumor at greater risk of exhibiting lymph node metastasis or a tumor with a lesser risk of exhibiting lymph node metastasis.Type: GrantFiled: April 20, 2017Date of Patent: October 5, 2021Assignees: OSLO UNIVERSITETSSYKEHUS HF, AKERSHUS UNIVERSITETSSYKEHUS HFInventors: Kjell-Inge Gjesdal, Endre Grøvik, Kathrine Røe Redalen, Tryggve Holck Storås
-
Patent number: 11078529Abstract: The present invention relates to methods and kits for the detection of 5-hydroxymethylcytosine (5hmC) and/or 5-methylcytosine (5meC). In some embodiments, the present invention relates to methods and kits for detection of 5hmC and/or 5meC in nucleic acid (e.g., DNA, RNA). In some embodiments, the present invention relates to detection of 5hmC in genomic DNA, e.g., mammalian genomic DNA.Type: GrantFiled: June 15, 2018Date of Patent: August 3, 2021Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: John Arne Dahl, Adam Brian Robertson, Arne Klungland, Linda Ellevog
-
Patent number: 10987011Abstract: The present invention relates to a method of identifying or monitoring circulatory failure in a subject, which method comprises assessing the subject's microcirculation in respect of the following parameters: (a) functional capillary density (FCD); (b) heterogeneity of the FCD; (c) capillary flow velocity; (d) heterogeneity of capillary flow velocity; (e) oxygen saturation of microvascular erythrocytes (SmvO2); and (f) heterogeneity of SmvO2; wherein parameters (a) to (d) are assessed visually by microscopy and parameters (e) and (f) are assessed by diffuse reflectance spectroscopy (DRS); well as apparatus and software designed for performance of such a method.Type: GrantFiled: January 28, 2014Date of Patent: April 27, 2021Assignee: OSLO UNIVERSITETSSYKEHUS HFInventor: Knut Kvernebo
-
Publication number: 20210069044Abstract: A patient isolator includes a base and a cover which is arranged to seal with the base. The cover is formed from a rigid material and has two access ports on an end face. The two access ports are angled in a width direction relative to a plane which extends parallel to the width direction of the patient isolator. The two access ports are angled relative to each other.Type: ApplicationFiled: September 16, 2020Publication date: March 11, 2021Applicant: Oslo Universitetssykehus HFInventors: Fridtjof Heyerdahl, Knut Erik Hovda, Espen Rostrup Nakstad, Arne Broch Brantsaeter, Ronald Rolfsen
-
Patent number: 10918817Abstract: There is provided a method of controlling a mechanical ventilator. The method may include the steps of receiving a measurement of transthoracic impedance of a patient obtained during chest compressions, determining a timing for a mechanical ventilator to provide a ventilation based on the measurement of transthoracic impedance, and sending a signal to control the mechanical ventilator based on the determined timing. There is also provided an apparatus for performing the method.Type: GrantFiled: July 21, 2014Date of Patent: February 16, 2021Assignee: Oslo Universitetssykehus HFInventor: Lars Wik
-
Patent number: 10806656Abstract: A patient isolator includes a base and a cover which is arranged to seal with the base. The cover is formed from a rigid material and has two access ports on an end face. The two access ports are angled in a width direction relative to a plane which extends parallel to the width direction of the patient isolator. The two access ports are angled relative to each other. A method of isolating a patient from an environment is also disclosed.Type: GrantFiled: November 14, 2016Date of Patent: October 20, 2020Assignee: Oslo Universitetssykehus HFInventors: Fridtjof Heyerdahl, Knut Erik Hovda, Espen Rostrup Nakstad, Arne Broch Brantsaeter, Ronald Rolfsen
-
Patent number: 10792216Abstract: A chest compression device for cardiopulmonary resuscitation comprises a support structure 2 for placement about a patient's chest and for holding a chest compressor 6 above a patient's sternum; a chest compressor 6 mounted on the support structure 2; and lateral chest supports 14 attached to the support structure 2 at points laterally either side of the chest when the device is in use, such that the lateral chest supports 14 will apply lateral pressure to the sides of the chest synchronized with a chest compression by the chest compressor 6.Type: GrantFiled: July 12, 2018Date of Patent: October 6, 2020Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Lars Wik, Morten Eriksen, Jo Kramer Johansen, Petter Andreas Steen, Kjetil Sunde
-
Patent number: 10716489Abstract: A method is described for determining biological tissue type based on a complex impedance spectra obtained from a probe with a conducting part adjacent a tissue region of interest, wherein the impedance spectra includes data from a number of frequencies. The method may include: obtaining, from the complex impedance spectra, a first data set representative of impedance modulus values, or equivalent admittance values, at one or more frequencies, obtaining, from the complex impedance spectra, a second data set representative of impedance phase angle values, or equivalent admittance values, at one or more different frequencies, applying a first discrimination criterion to the first data set, applying a second discrimination criterion to the second data set, and thereby determining if the tissue region of interest is a tissue type characterised by the discrimination criteria.Type: GrantFiled: October 12, 2015Date of Patent: July 21, 2020Assignee: Oslo Universitetssykehus HFInventors: Håvard Kalvøy, Axel Sauter, Audun Stubhaug, Sverre Grimnes, Ørjan G. Martinsen
-
Patent number: 10695371Abstract: The present invention relates to the use of a photoactivatable Porphyrin-Derivative in extracorporeal photophoresis (ECP) treatment, in which a patient's blood or part of it containing sad Porphyrin-derivative is/are exposed to light of a wavelength which activates said photoactivatable Porphyrin-Derivative.Type: GrantFiled: April 24, 2015Date of Patent: June 30, 2020Assignee: Oslo Universitetssykehus HFInventors: Qian Peng, Trond Warloe, Jahn M. Nesland, Eidi Christensen, Odrun Arna Gederaas, Toril Holien
-
Patent number: 10677794Abstract: The present invention relates to compositions and methods for visualizing disease-specific T-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory T-cells.Type: GrantFiled: May 14, 2014Date of Patent: June 9, 2020Assignee: OSLO UNIVERSITETSSYKEHUS HFInventors: Ludvig Sollid, Shuo-wang Qiao, Asbjorn Christophersen, Knut E. A. Lundin
-
Patent number: 10598663Abstract: The present invention relates to methods and biomarkers (e.g., protein biomarkers) for detection of colorectal cancer in biological samples (e.g., tissue samples, biopsy samples, stool samples, blood samples, plasma samples, serum samples). In some embodiments, methods and biomarkers of the present invention find use in detection of colon cancer, providing a prognosis to colorectal cancer patients, and in companion diagnostics.Type: GrantFiled: April 10, 2015Date of Patent: March 24, 2020Assignee: Oslo Universitetssykehus HFInventors: Ragnhild A. Lothe, Jarle Bruun, Matthias Kolberg, Rolf Inge Skotheim, Guro Elisabeth Lind, Arild Nesbakken